Lenire sponsors Tinnitus Week 2025

Lenire proudly sponsors Tinnitus UK Tinnitus Week 2025

 Lenire by Neuromod Devices is proud to continue our sponsorship of Tinnitus UK’s Tinnitus Week Campaign. Tinnitus Week 2025 raises the alarm on the current status of tinnitus care in the United Kingdom.

Tinnitus affects an estimated 8 million people in the UK¹ but, according to Tinnitus UK’s latest report, tinnitus patients face delays of up to three years for ENT referrals. According to the report, many audiologists may require additional training to confidently treat tinnitus.

As a result, many tinnitus patients wait a significant amount of time, and discover their options are limited once they attend an appointment.

Lenire increasing tinnitus clinic partnerships in UK

Increasing access to tinnitus care services, and the number of clinically proven treatment options is critical to improving tinnitus care in the UK. To meet the unmet demand for tinnitus care, Neuromod is partnering with 4 additional UK clinics to expand Lenire’s availability.

Lenire^® is a bimodal neuromodulation device which has been proven to provide long lasting relief from tinnitus across multiple clinical trials. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.

This latest expansion doubles the number of clinics providing Lenire in the UK, adding new partnerships with Harley Street Hearing in London, Alto Hearing and Tinnitus in Kenilworth, Durham Hearing Specialists in Durham, and Aberystwyth Hearing in Aberystwyth.

“Sponsoring Tinnitus Week ensures that the nearly 9 million people living with tinnitus in the UK continue to have access to tinnitus management resources and information from Tinnitus UK,” said Neil Doyle, Neuromod VP of Marketing. “Partnerships with leading UK tinnitus clinics increases care accessibility, and the number of tinnitus treatment options available to tinnitus patients regardless of where they are at in the tinnitus treatment lifecycle.”

Increasing accessibility to clinically proven treatments

Lenire has been proven safe and effective across three large-scale clinical trials involving 600+ patients.

Lenire’s most recent clinical trial, TENT-A3, was a controlled clinical trial that compared Lenire to sound-only therapy, which was the trial’s control. TENT-A3 was conducted as part of Lenire’s successful De Novo submission to the US FDA. Lenire was shown to be clinically superior to sound-only for the majority of patients with bothersome tinnitus.²

Results from Lenire’s second large-scale clinical trial, TENT-A2, were published in the scientific journal, Nature – Scientific Reports. 95% of compliant patients reported a tinnitus improvement, 91% of whom reported a sustained improvement for a year after treatment.^3,5

Analysis of 220 real world Lenire patients further validated Lenire’s effectiveness as a tinnitus treatment device. The pre-published paper showed that 91.5% of patients at Alaska Hearing and Tinnitus Center had a clinically significant reduction in tinnitus after 12-weeks of treatment with Lenire.^{4, 5}

Book a tinnitus assessment

Lenire is now available through clinics across the UK. You can find a nearby clinic, and book a tinnitus assessment to see if Lenire is right for you and get advice on managing tinnitus by visiting www.lenire.com/find-a-clinic.